PRECAUTIONS, IMPLICATIONS AND CONTRAINDICATIONS: USING EVIDENCE TO ESTABLISH A NURSING PROTOCOL FOR A RECOMBINANT POXVIRUS (VACCINIA/FOWLPOX) BASED VACCINE PROGRAM

5.00
Hdl Handle:
http://hdl.handle.net/10755/165254
Category:
Abstract
Type:
Presentation
Title:
PRECAUTIONS, IMPLICATIONS AND CONTRAINDICATIONS: USING EVIDENCE TO ESTABLISH A NURSING PROTOCOL FOR A RECOMBINANT POXVIRUS (VACCINIA/FOWLPOX) BASED VACCINE PROGRAM
Author(s):
Green, Robin; Condon, Jessie; McCaffrey, Kathleen; Lesko, Zenona
Author Details:
Robin Green, RN BSN MSN OCN, Clinical Nurse Specialist, NYU Cancer Institute, New York City, New York, USA, email: robin.green@nyumc.org; Jessie Condon, RN, BSN, OCN, Yale University School of Nursing, New Haven, Connecticut; Kathleen McCaffrey, RN, MSN, OCN; Zenona Lesko, RN, BSN
Abstract:
Vaccine therapy hypothesizes when a cancer patient is vaccinated with a primary vector and a tumor-specific antigen, the antigens will stimulate the patientÆs immune system to recognize and attack the cancer cells, sparing healthy cells. To induce this immune response, the poxviruses are among the most commonly studied vectors. Vaccinia is considered the prototypical poxvirus. Vaccinia vaccine is a live virus and classified as a Biosafety Level 2 Agent by the Center for Disease Control. These agents are associated with human disease and present a potential hazard to people and the environment. Government (CDC and NCI) mandated regulations, as well as institutional concerns, challenged the oncology nurses in our facility to deliver optimal patient care while ensuring the ôsafetyö of personnel, immunocompromised patientÆs and the environment. This paper will describe the development and implementation of an evidence-based protocol integrating biosafety regulations with nursing expertise To develop an evidence-based nursing protocol that would define safe practice for personnel involved in the management of patients receiving recombinant poxvirus vaccines. A multidisciplinary task force was formed and included Nursing, Oncology, Infectious Disease, Environmental Services, Employee Health, and Pharmacy. A literature review, including Medline databases and NCI/CDC websites was conducted. An evidence-based protocol was synthesized from a critique of the literature, recommendations from the task force and the ECOG protocol. A patient education tool was written. Education was provided for all personnel involved in caring for protocol patients. To ensure compliance a competency based checklist was developed for the nursing staff. We opened the vaccinia trial the fall of 2006. The total accrual will be 10 patients. Currently, 2 patients are being screened and 3 patients are enrolled. All enrolled patients received the vaccinia injection without incident. The coordinated efforts of all departments provided for streamlined treatment days. This clinical trial with its myriad of biosafety precautions, patient care implications and protocol contraindications could intimidate the most experienced researcher. Oncology nurses play a pivotal role in transforming ôcutting-edgeö science into clinical practice. Following the evidence was an invaluable strategy in implementing our nursing protocol.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titlePRECAUTIONS, IMPLICATIONS AND CONTRAINDICATIONS: USING EVIDENCE TO ESTABLISH A NURSING PROTOCOL FOR A RECOMBINANT POXVIRUS (VACCINIA/FOWLPOX) BASED VACCINE PROGRAMen_GB
dc.contributor.authorGreen, Robinen_US
dc.contributor.authorCondon, Jessieen_US
dc.contributor.authorMcCaffrey, Kathleenen_US
dc.contributor.authorLesko, Zenonaen_US
dc.author.detailsRobin Green, RN BSN MSN OCN, Clinical Nurse Specialist, NYU Cancer Institute, New York City, New York, USA, email: robin.green@nyumc.org; Jessie Condon, RN, BSN, OCN, Yale University School of Nursing, New Haven, Connecticut; Kathleen McCaffrey, RN, MSN, OCN; Zenona Lesko, RN, BSNen_US
dc.identifier.urihttp://hdl.handle.net/10755/165254-
dc.description.abstractVaccine therapy hypothesizes when a cancer patient is vaccinated with a primary vector and a tumor-specific antigen, the antigens will stimulate the patientÆs immune system to recognize and attack the cancer cells, sparing healthy cells. To induce this immune response, the poxviruses are among the most commonly studied vectors. Vaccinia is considered the prototypical poxvirus. Vaccinia vaccine is a live virus and classified as a Biosafety Level 2 Agent by the Center for Disease Control. These agents are associated with human disease and present a potential hazard to people and the environment. Government (CDC and NCI) mandated regulations, as well as institutional concerns, challenged the oncology nurses in our facility to deliver optimal patient care while ensuring the ôsafetyö of personnel, immunocompromised patientÆs and the environment. This paper will describe the development and implementation of an evidence-based protocol integrating biosafety regulations with nursing expertise To develop an evidence-based nursing protocol that would define safe practice for personnel involved in the management of patients receiving recombinant poxvirus vaccines. A multidisciplinary task force was formed and included Nursing, Oncology, Infectious Disease, Environmental Services, Employee Health, and Pharmacy. A literature review, including Medline databases and NCI/CDC websites was conducted. An evidence-based protocol was synthesized from a critique of the literature, recommendations from the task force and the ECOG protocol. A patient education tool was written. Education was provided for all personnel involved in caring for protocol patients. To ensure compliance a competency based checklist was developed for the nursing staff. We opened the vaccinia trial the fall of 2006. The total accrual will be 10 patients. Currently, 2 patients are being screened and 3 patients are enrolled. All enrolled patients received the vaccinia injection without incident. The coordinated efforts of all departments provided for streamlined treatment days. This clinical trial with its myriad of biosafety precautions, patient care implications and protocol contraindications could intimidate the most experienced researcher. Oncology nurses play a pivotal role in transforming ôcutting-edgeö science into clinical practice. Following the evidence was an invaluable strategy in implementing our nursing protocol.en_GB
dc.date.available2011-10-27T12:15:15Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:15:15Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.